Objective: The aim of this study was to evaluate tumor characteristics, management and survival in elderly male breast cancer patients in comparison with younger men. Methods: We reviewed medical records of 99 male breast cancer patients between 1972 and 2011. The median age of the patients was 64.5 years. Patient characteristics including clinicopathologic factors, treatment modalities, survival and prognostic factors were evaluated. Patients were subdivided into two groups according to their age (young, ,65 years; old, 65 years) and compared based on these factors. Results: Elderly male breast cancer patients had larger tumors in more advanced stages at the time of diagnosis compared with younger patients. In spite of the larger tumors at presentation, older patients had tumors with more favorable biological characteristics, such as higher ratio of estrogen and progesterone receptor expression. Ten-year cancer-specific survival for older patients was 49.2% compared with 55.8% in younger men (P ¼ 0.8). Prognostic factors influencing overall survival in univariate analysis were: the presence of metastatic axillary lymph nodes (P ¼ 0.0001), T stage (P ¼ 0.001) and age 65 years. Multivariate analysis indicated T stage (P ¼ 0.008) and N stage (P ¼ 0.038) as the significant negative prognostic factors for overall survival. Although surgery, radiotherapy and hormone therapy were equally utilized in old and young patients, old patients were less likely to receive adjuvant chemotherapy. Conclusions: Our study demonstrated the differences in the clinical and biological characteristics of male breast cancer according to the age of the patients.
INTRODUCTION
Male breast cancer (MBC) is a rare disease accounting for ,1% of all breast cancer cases (1) . MBC constitutes ,1% of all cancer in men responsible for ,0.5% of all cancerrelated male deaths (2) . Over the past 25 years, the incidence of MBC has been increasing gradually (3) . National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) in the USA showed an increase in the incidence of MBC from 0.86 to 1.08 per 100 000 men between 1973 and 1998 (3). The incidence of MBC has also been increasing in other parts of the world besides the USA and Canada (4) . The prevalence of MBC increases with age. The average age of diagnosis in males is 60 years. Males are diagnosed approximately a median of 10 years older than female breast cancer patients (5 -7) .
Management of breast cancer in women has changed dramatically over time. The use of more effective hormonal and chemotherapeutic agents and the introduction of anti-Her2 treatment have revolutionized and improved the treatment of breast cancer. The use of chemotherapy and hormone therapy increased over time. However, MBC still carries a dismal prognosis.
There have been studies reporting tumor characteristics and clinical outcome in elderly women with breast cancer (8 -10) . However, there is a paucity of published literature investigating the relation of age with tumor characteristics and survival in MBC. The aim of this study is to evaluate the treatment results of MBC in relation to tumor characteristics, management and survival in elderly patients compared with younger ones.
PATIENTS AND METHODS

PATIENTS
We retrospectively reviewed and analyzed the data of male patients treated for breast cancer in Istanbul University Cerrahpasa Medical Faculty from 1972 through 2011. We routinely collected information regarding age, date of diagnosis, time to diagnosis, staging procedures (bone scan, thorax and abdomen tomography), surgical procedures, pathology, treatment modality, recurrence date, second cancers and causes of death.
Patients underwent surgery either by segmental mastectomy or by modified radical mastectomy (MRM) with sentinel lymph node sampling and/or complete lymph node dissection. Adjuvant treatment was based on tumor characteristics, comorbid conditions and age. Adjuvant chemotherapy was used in 27 young (56%) and 16 (31%) elderly patients. The most common chemotherapy regimen was standard doxorubicin (60 mg/m 2 ) þ cycplophophamide (600 mg/m 2 ) (AC) in 79% of the patients. Four cycles of adjuvant AC was given on Day 1 of every 21-day cycle. Adjuvant radiotherapy (RT) was given to patients who had breast-conserving surgery or who had axillary lymph node involvement or large tumors. The median total dose of RT was 50 Gy with a daily fraction dose of 2 Gy. Finally, tamoxifen 20 mg/day was given as standard adjuvant hormonal therapy for 5 years or until disease recurrence.
Surveillance was carried out on regular basis with clinical and radiologic methods per clinical guidelines of the time. Relapsed disease was verified histopathologically, where possible, in patients with radiologic evidence of recurrence.
METHODS
Pathology investigations include evaluation of primary tumor and lymph nodes. Estrogen receptor (ER), progesterone receptor (PR) and Her2 status were evaluated by immunohistochemistry (IHC) and silver in situ hybridization (SISH).
ER, PR and Her2 status were documented in the patient files. In patients who did not have these data on the file, archived material was tested where possible. However, some of the materials were lost or decomposed. Therefore, we could not look for any changes in the receptor status over time.
Monoclonal murine anti-estrogen receptor protein antibody (Neomarks, Clone SP1, 1/400 dilution) and antiprogesterone receptor protein antibody (Novo Castra, 1A6, 1/ 100 dilution) were used. The nuclear staining pattern 1% was considered positive. Monoclonal murine anti-Her2 antibody (Novo Castra, CBE-356 1/100 dilution) was used for IHC. The membranous staining pattern was evaluated based on the guidelines of 'American Society of Clinical Oncology, College of American Pathologists'. SISH was performed using Ventana Benchmark XT or LT device in patients with 2þ staining pattern by IHC.
STUDY DESIGN AND STATISTICAL ANALYSIS
We divided the patients into two groups based on their age (young group with age ,65 years and old group with age 65 years). We compared clinicopathologic factors including histological subtype, tumor size, axillary lymph node metastases, hormone receptors status, treatment delivery, local recurrence rate and survival in these groups.
Overall and cancer-specific survival and local control rate (OS, CSS and LCR) were calculated from the date of diagnosis. OS was defined as the time of death from any cause and CSS was defined as the time of death from MBC. LCR was defined as the time until locoregional relapse.
Categorical and continuous variables among two groups were summarized using descriptive statistics (e.g. median, range, frequency and percentage) and compared with x 2 and Mann -Whitney U tests, respectively. OS and CSS rates as well as LCRs were estimated by the Kaplan -Meier method. The effects of clinical variables on OS were assessed with univariate analysis. The log-rank test was used to compare curves for univariate analysis. A Cox proportional hazards model was used to assess independent prognostic factors for OS. All analyses were performed using the SPSS 15.0 (SPSS, Inc., Chicago, IL, USA) software. The statistical level of significance was defined as P , 0.05.
Approval from the local ethics committee and informed consent of the patients or their next of kin were obtained prior to the study.
RESULTS
CLINICAL AND PATHOLOGICAL CHARACTERISTICS
A total of 99 patients with nonmetastatic MBC who underwent surgery were referred for a multidisciplinary evaluation. The median age of all MBC was 64.5 years for our cohort. Forty-eight patients (48.5%) were ,65 years old and 51 patients (51.5%) were 65 years old. Clinical characteristics of the patients are shown in Table 1 .
The median follow-up period was 68 months (range, 8 -172 months) and 63 months (range, 6 -192) for young and old patients, respectively.
Older patients had larger tumors (P ¼ 0.003) and more advanced stage (P ¼ 0.002) at the diagnosis than younger patients. Tumor histology, lymph node involvement, neural and lymphovascular invasion were similar in both groups (P ¼ NS). In spite of the larger tumors at presentation, older patients had tumors with more favorable biological characteristic compared with younger patients (higher ratio of ER and PR receptor expression, P ¼ 0.001).
TREATMENT MODALITIES AND RESPONSE Treatment modalities applied to MBC patients are summarized in Tables 2 and 3 . Briefly, all MBC patients underwent surgery. The most common type of surgical treatment procedure was MRM (70%) followed by breast-conserving surgery (30%). Type of surgery was similar in older versus younger patients (P ¼ 0.15). Eighty-two patients (82.8%) (young group n ¼ 40 versus old group n ¼ 42, P ¼ 0.1) received adjuvant RT to the surgical site plus lymphatics because of high-risk factors. The median total RT dose was 50 Gy with a daily fraction dose of 2 Gy.
Adjuvant chemotherapy was administered to 43 patients (43%) (young group n ¼ 27 (56%) versus old group n ¼ 16 (31%), P ¼ 0.015). Older patients were offered chemotherapy less often despite a larger tumor size. The most common chemotherapy regimens were antracycline-based schedules (71%). The use of adjuvant hormonal therapy was similar in both age groups (P ¼ 0.17).
SURVIVAL AND UNIVARIATE ANALYSIS
All patients were analyzed for survival. During follow-up, 25 (52%) patients in the young age group and 32 (62.7%) patients in the old age group died of any cause. Breast cancer-related deaths were similar in both age groups (19 (39.6%) in young group versus 17 (33.3%) patients in old group; P ¼ 0.8). However, deaths due to other causes 24 Male breast cancer in elderly patients (cardiovascular and thromboembolic events) were more frequent in older patients (15 (29.4%) versus younger ones (6 (12.5%)) (P ¼ 0.04). Moreover, secondary malignancies were more common in older men (n ¼ 6, 11%) compared with younger ones (n ¼ 3, 6.2%). We observed secondary lung (n ¼ 3), prostate (n ¼ 3), gastric (n ¼ 2), esophagus (n ¼ 1) and pancreatic (n ¼ 1) cancers. Five-and 10-year cancer-specific survival for all MBC patients were 75.2 and 52.5%, respectively. Cancer-specific survival was similar between the two groups (P ¼ 0.7) (Fig. 1) . For young MBC patients, 5-and 10-year CSS were 78.6 and 72.4%, respectively. Similarly, for old patients, the corresponding numbers were 55.8 and 49.2%, respectively.
Five-and 10-year OS were significantly poor in older patients compared with younger ones (61 and 28% versus 68 and 52%) (P ¼ 0.03) (Fig. 2) . Five-year LCRs were similar in both age groups (92 versus 89%; P ¼ 0.7). The most common locoregional relapse sites were chest wall (48.4 versus 49.2), supraclavicular area (42 versus 44%) and axilla (23.6 versus 25.2) with no difference according to the age group (P ¼ 0.8).
In univariate analysis, poor prognostic factors influencing OS were involvement of axillary lymph nodes (P ¼ 0.0001), higher T stage (P ¼ 0.001) and age 65 year old (Table 4) . ER and PR status, and tumor grade had no affect on OS (data not shown). Based on the results from univariate analysis, we performed multivariate analysis using the Cox proportional hazard model (Table 5 ). T stage (P ¼ 0.008) and N stage (P ¼ 0.03) were significantly poor prognostic factors for OS in multivariate analysis. Older age was also associated with a trend for poor OS (P ¼ 0.067). We also performed multivariate analysis for breast cancer-specific survival (Table 6 ). T stage (P ¼ 0.03) and N stage (P ¼ 0.013) were the only significant independent prognostic factors for cancer-specific survival.
DISCUSSION
Patients with MBC are diagnosed at a median age of 60 years, which is higher than the median age at diagnosis for women with breast cancer (5 -7). However, MBC can be seen at any age (11). The incidence of MBC increases with advancing patient age, climbing steadily until a plateau is reached at the age of 80 years (11, 12) .
Gennari et al. showed that elderly women with breast cancer had more favorable biological characteristics compared with younger women such as high ER/PR expression, less peritumoral invasion and low HER2/neu expression. However, elderly women with breast cancer had larger tumors and more extensive lymph node involvement (13) . Similarly, Diab et al. demonstrated that advancing age is associated with more favorable tumor biology in female breast cancer (14) . But there is a paucity of published literature for MBC with age and tumor characteristic. We compared clinical and histopathologic variables of men with breast cancer according their age of presentation. We found similar results that showed older males had more ER/PR expression and larger tumor size. Tumor grading was similar between groups possibly due to the low patient number and absence of grading data in a substantial portion of the patients. We demonstrated that clinical and biological characteristics of the MBC alter with age.
An international population-based study of MBC reported 5-and 15-year OS of 72 and 50%, respectively (15) . Our results of 75.2% 5-year and 52.5% 10-year OS are in striking correlation with these data. Several factors affect prognosis in MBC patients. However, tumor stage and axillary nodal status have been shown to be the most important independent predictors of OS (16) . Giordano et al. showed 5-and 10-year survival rates of 63 and 41%, respectively. In both univariate and multivariate analyses, age 65 years, large (17, 18) . Treatment modalities such as surgery, RT and hormone therapy were used equally in old and young MBC patients. In our cohort, 83% of the patients received RT with 8 and 11% local recurrence rates in both the groups (P ¼ 0.7). Similar findings regarding RT in MBC was reported in the literature (19, 20) . However, elderly patients were less likely to receive chemotherapy in our study (31 versus 56%, P ¼ 0.015). This may be explained in part with the presence of favorable tumor characteristics such as high ER/PR expression in these patients. But, larger tumor size and higher tumor stage in elderly patients argue against this explanation.
In conclusion, we demonstrated that older age group patients (65 years) compared with younger patients (,65 years) had a larger tumor size and more advanced stage, but more favorable biological characteristics (higher ER and PR expression). Older patients had poor survival mainly due to non-cancer-related deaths with similar CSS with younger patients. Both T and N stages had independent significant negative effect on OS and patients aged 65 years had a shorter survival trend. Another important finding was the confirmation that old patients were less likely to receive adjuvant chemotherapy. Considering the high death rate due to nonneoplastic causes in elderly patients, more aggressive treatment approaches probably are not required. The main limitations of this study were its retrospective design, small cohort of patients and missing data especially on hormone receptors and Her2 status. Further research is needed to define better diagnostic and therapeutic tools in MBC patients.
